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1525-0016/$To evaluate the use of alphavirus vectors for tumor treatment we have constructed and compared
two Semliki Forest virus (SFV) vectors expressing different levels of IL-12. SFV-IL-12 expresses both
IL-12 subunits from a single subgenomic promoter, while in SFV-enhIL-12 each IL-12 subunit is
expressed from an independent subgenomic promoter fused to the SFV capsid translation
enhancer. This latter strategy provided an eightfold increase of IL-12 expression. We chose the
poorly immunogenic MC38 colon adenocarcinoma model to evaluate the therapeutic potential of
SFV vectors. A single intratumoral injection of 108 viral particles of SFV-IL-12 or SFV-enh-IL-12
induced z80% complete tumor regressions with long-term tumor-free survival. However, lower
doses of SFV-enhIL-12 were more efficient than SFV-IL-12 in inducing antitumoral responses,
indicating a positive correlation between the IL-12 expression level and the therapeutic effect.
Moreover, repeated intratumoral injections of suboptimal doses of SFV-enhIL-12 increased the
antitumoral response. In all cases SFV vectors were more efficient at eliminating tumors than a first-
generation adenovirus vector expressing IL-12. In addition, the antitumoral effect of SFV vectors
was only moderately affected by preimmunization of animals with high doses of SFV vectors. This
antitumoral effect was produced, at least partially, by a potent CTL-mediated immune response.R
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One of the most effective antitumoral cytokines is
interleukin 12 (IL-12) [1], a protein composed of two
subunits, p35 and p40, which is expressed by macro-
phages and dendritic cells. IL-12 has shown a strong
antitumoral activity [2] mediated by the activation of T,
NK, and NKT cells and by an antiangiogenic effect [3,4].
However, IL-12 expression may cause toxicity, due to the
induction of IFN-g [5]. Strategies allowing local expres-
sion of IL-12 in tumors have been developed, giving rise
to high antitumoral efficacy with reduced toxicity. Intra-
tumoral gene expression can be achieved by transducing
tumor cells with vectors encoding the desired gene [6,7].
Alphavirus-based vectors have emerged as a promis-
ing tool for cancer gene therapy due to several advan-
tages such as: (i) very high expression levels, (ii) high
infectivity in many different cell types, (iii) low immu-
nogenicity against the vector, (iv) induction of apopto-
sis, and (v) a relatively easy manipulation. AlphavirusesTHERAPY Vol. 12, No. 1, July 2005
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.00are enveloped viruses carrying a single positive-strand
RNA genome of about 12 kb [8]. In the present study we
have used an expression system based on the alphavirus
SFV (Semliki Forest virus) in which the region coding for
the structural proteins is replaced by a heterologous
gene [9]. Recombinant SFV RNA can be transcribed in
vitro and transfected into cells, leading to its replication
and to the production of a subgenomic RNA from which
the heterologous protein will be expressed at very high
levels. The SFV expression level can be increased about
eightfold by fusing the gene of interest with the trans-
lational enhancer derived from the SFV capsid gene [10].
The enhancer sequence (b1) used in this study com-
prises the first 102 nucleotides of the SFV capsid gene,
giving rise to a 34-amino-acid tail at the N-terminal end
of the recombinant protein. A strategy to remove this
tail is based on the use of the foot and mouth disease
virus (FMDV) 2A autoprotease cloned as a linker
between the enhancer and the gene of interest [11].153
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particles (vp) by cotransfecting it into cells together
with two helper RNAs coding for the capsid and the
envelope proteins, respectively [11]. Vectors based on
alphaviruses have been successfully used in vaccination
studies in different animal models [12]. These studies
have also included the use of alphavirus vectors as
antitumoral vaccines. In this case alphavirus vectors
expressing tumor-associated antigens have been shown
to be able to protect animals efficiently against a
challenge in various tumor models [13–22]. Studies in
which alphavirus vectors have been used for therapeutic
treatment of tumors have been mostly based on
expression of cytokines, such as IL-12 [23–25] and
endostatin [26], or on the use of dendritic cells
transduced with SFV vectors expressing cytokines
[27,28] in murine tumor models. Although in some
cases alphavirus vectors were able to inhibit tumor
growth the results have been somewhat variable, which
might be due to the use of low doses of vector, leading
to a low expression of the therapeutic cytokines in the
tumor, as well as to a low induction of apoptosis in
tumor cells. This last property of alphavirus has also
been used by itself to mediate antitumoral responses, by
treating tumors with vectors expressing reporter genes
[25,29] or SFV viral structural proteins [30].
In this work, we have tested the therapeutic potential
of two SFV vectors expressing different levels of IL-12 in
a poorly immunogenic tumor model of mouse colon
adenocarcinoma. We have used a strategy to increase
the expression level of IL-12 based on the fusion of this
protein with the SFV capsid translation enhancer, which
has led to a very high antitumoral efficiency using
relatively low doses of vector. In addition we have
shown that in our tumor model SFV vectors expressing
IL-12 were more potent than a first-generation adeno-
virus vector expressing the same cytokine. Finally, SFV
vectors were able to mediate antitumoral responses even
in animals having high titers of circulating anti-SFV
antibodies.
RESULTS AND DISCUSSION
Construction and Characterization of SFV Vectors
Expressing IL-12
To express murine IL-12 from the SFV vector we cloned a
cassette containing p35 and p40 ORFs separated by an
IRES sequence into pSFV-1 under the control of the viral
subgenomic promoter, generating pSFV-IL-12 (Fig. 1A).
To increase the expression level of IL-12 we generated a
second vector (pSFV-enhIL-12) in which each IL-12
subunit gene was cloned downstream of an independent
viral subgenomic promoter fused with the minimal SFV
capsid translation enhancer (Fig. 1A). To compare IL-12
expression from these two vectors, we transcribed RNAs
from each plasmid with SP6 polymerase and electro-154porated them into BHK-21 cells. We pulse-labeled trans-
fected cells 12 h after electroporation with a mixture of
[35S]methionine and [35S]cysteine for 15 min and chased
at different times. The strong shut-off of host cell protein
synthesis observed in electroporated cells (Fig. 1B)
indicated a high transfection efficiency, which was
confirmed by X-gal staining of cells transfected with
SFV-LacZ RNA (Fig. 1D). After a 5-min chase bands
corresponding to p35 and p40 could be detected in cell
lysates with both IL-12 vectors (Fig. 1B, upper gel, lanes 1
and 3). However, after a 7-h chase p35 and p40 were
present mostly in supernatants (Fig. 1B, lower gel, lanes 2
and 4) due to secretion of the cytokine. Expression of p35
and p40 was higher in cells transfected with SFV-enhIL-
12, indicating a correct functioning of the translational
enhancer. Both p70 heterodimer and p40 monomer were
also specifically detected by Western blot analysis with a
p40-specific antibody in cells transfected with SFV
vectors expressing IL-12 (Fig. 1C, upper gel, lanes 2 and
4). To quantify IL-12 expression from both SFV vectors,
we collected supernatants from BHK-21-transfected cells
at different times postelectroporation and quantified IL-
12 p70 by ELISA (Fig. 1E). IL-12 concentration increased
over time in cells transfected with both SFV vectors,
reaching a peak of 17 F 0.76 Ag/106 cells for SFV-IL-12
and 126 F 3.61 Ag/106 cells for SFV-enhIL-12 at 72 h
posttransfection. No IL-12 was detected in supernatants
of cells transfected with SFV-LacZ RNA (data not shown).
The difference in expression between SFV-IL-12 and SFV-
enhIL-12 could be due to the fact that IRES-mediated
translation is less efficient than cap-dependent ribosome
scanning. However, there are several pieces of evidence
indicating that differences in expression are most prob-
ably due to the translation enhancer used in SFV-enhIL-
12. First, in an SFV vector expressing p35 and p40 from
two independent subgenomic promoters described pre-
viously [23,24] the level of IL-12 expression was only
about half the level we observed with our IRES SFV-IL-12
vector. Second, it has been reported that the b1 enhancer
provides about an eightfold increase in the expression
level when it is fused to a recombinant protein in the SFV
vector [10], which is similar to the increase that we have
observed comparing IL-12 expression between SFV-IL-12
and SFV-enhIL-12. We checked the biological activity of
recombinant IL-12 produced from SFV vectors by induc-
tion of IFN-g secretion in mouse splenocytes (data not
shown).
Infection of MC38 Colon Adenocarcinoma Cells with
SFV Vectors in Vitro and in Vivo
To test the antitumoral potential of the SFV recombinant
vectors described above we chose the MC38 murine colon
adenocarcinoma model, which has been described as
poorly immunogenic and less prone to undergo regres-
sion in protocols using IL-12 [31–33]. First, we inves-
tigated the ability of SFV vp to infect MC38 cells in vitro.MOLECULAR THERAPY Vol. 12, No. 1, July 2005
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FIG. 1. Schematic representation of recombinant SFV vectors expressing IL-12 and in vitro analysis of expression. (A) SFV-IL-12 carries, downstream of the viral
subgenomic promoter (sg Pr), a cassette containing p35 and p40 ORFs separated by the encephalomyocarditis virus IRES sequence. SFV-enhIL-12 carries each IL-
12 gene downstream of an independent subgenomic promoter fused in-frame with a sequence coding for the minimal SFV capsid translation enhancer (enh),
using the FMDV 2A autoprotease sequence (2A) as a linker. Black squares at both ends, 5V and 3V sequences necessary for replication. (B) Metabolic labeling of
IL-12. At 12 h posttransfection with in vitro synthesized RNAs, cells were pulse-labeled with a mixture of [35S]methionine and [35S]cysteine for 15 min and chased
for 5 min (lanes 1 and 3) or 7 h (lanes 2, 4, and 5). Cell lysates (upper gel) and supernatants (lower gel) were analyzed by SDS–PAGE followed by
autoradiography. MW, molecular weight markers. (C) Western blot analysis of the same samples used for metabolic labeling. A p40-specific antibody was used to
analyze supernatants (upper gel), while an actin-specific antibody was used to analyze lysates as an internal control (lower gel). In B and C cells were
electroporated with SFV-IL-12 (lanes 1 and 2), SFV-enhIL-12 (lanes 3 and 4), or SFV-LacZ (lane 5) RNAs. (D) Evaluation of transfection efficiency. Cells
electroporated with SFV-LacZ were stained with X-gal 24 h after transfection. (E) IL-12 concentration in supernatants from cells transfected with recombinant SFV
vectors. Supernatants were collected at different times and IL-12 concentration was measured by p70-specific ELISA. The differences between SFV-IL-12- and
SFV-enhIL-12-transfected cells were statistically significant (*P b 0.05).
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described under Materials and Methods and used them
to infect MC38 cells at different m.o.i. We also used aMOLECULAR THERAPY Vol. 12, No. 1, July 2005
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IL-12) as a control to infect MC38 cells at different m.o.i.
We measured IL-12 concentration in supernatants of SFV-155
ARTICLE doi:10.1016/j.ymthe.2005.02.011infected cells at 24 h p.i. (postinfection), which demon-
strated IL-12 production to be dose dependent (Fig. 2A).
SFV-enhIL-12 provided the maximum level of expression
(124 Ag IL-12/106 cells), which was similar to that
observed in BHK cells. In the case of Ad-IL-12 a m.o.i.
of 1000 was necessary to express about half the amount
of IL-12 observed with SFV-IL-12 at m.o.i. of 100,
probably indicating a lower infectivity of this virus in
MC38 cells (data not shown). To study in vivo infectivity
of SFV vectors, we established subcutaneous MC38
nodules in syngeneic C57BL/6 mice. When tumors
reached a 5-mm diameter, we injected them with 108
vp of SFV vectors expressing firefly luciferase (SFV-Luc) orFIG. 2. In vitro and in vitro infectivity of SFV vectors
in MC38 tumor cells. (A) 5  104 MC38 cells were
infected in vitro at m.o.i. of 1, 10, or 100 with SFV-
enhIL-12 or SFV-IL-12 vp and at 24 h p.i. IL-12
concentration was measured in supernatants by
specific p70 ELISA. The differences between SFV-IL-
12- and SFV-enhIL-12-infected cells were statisti-
cally significant (*P b 0.05). (B) Subcutaneous
MC38 tumor nodules implanted in syngeneic mice
were intratumorally injected with 108 vp of SFV-Luc
and luciferase expression was analyzed with an IVIS
CCD camera as described (left picture corresponds
to a representative mouse visualized at day 2 p.i.).
Luciferase activity was measured (photons/s) in
tumor areas and represented as group mean F
SD (right graph, n = 3). A group of tumor-bearing
mice was mock infected and used as a negative
control. The differences between SFV-Luc- and
mock-treated mice were statistically significant
(*P b 0.05). (C) C57BL/6 tumor-bearing mice were
intratumorally injected with 108 vp of SFV-LacZ and
at 24 h p.i. tumors were removed and processed for
X-gal staining. Blue cells indicate infected cells in
the tumor mass (the picture corresponds to a
representative mouse). tm, limit of the tumor mass;
ic, infected cells along the needle trajectory.
156h-galactosidase (SFV-LacZ). Animals inoculated with SFV-
Luc were visualized with a CCD camera showing a high
luciferase activity specifically in tumors for at least 6 days
after infection (Fig. 2B). We also tested homogenates of
tumor nodules for luciferase expression using a conven-
tional luminometer, resulting in an expression level
about 1000 times higher than that observed in tumor-
adjacent muscle (data not shown), indicating a very low
leakiness of the vector from the tumor mass. These results
show that SFV vectors can infect MC38 cells in vivo,
mediating a high local transgene expression in the
tumor. To determine the number of infected cells after
intratumoral injection, we treated tumors with 108 vp ofMOLECULAR THERAPY Vol. 12, No. 1, July 2005
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ARTICLEdoi:10.1016/j.ymthe.2005.02.011SFV-LacZ, processed them at 24 h p.i., and analyzed them
by X-gal staining (Fig. 2C). This analysis revealed that
only a relatively small number of tumor cells were
infected, located mainly along the needle trajectory.
Antitumoral Efficacy of SFV-IL-12 and SFV-enhIL-12 in
the MC38 Tumor Model
To evaluate the antitumoral efficacy of SFV vectors coding
for IL-12, we established subcutaneous MC38 tumors in
C57BL/6 mice and treated them with a single intra-
tumoral injection of 107, 5  107, or 108 vp of either
SFV-IL-12 or SFV-enhIL-12 (Fig. 3A). We treated parallel
groups of mice with Ad-IL-12 at doses of 107, 5  107, or
108 plaque-forming units (PFU) to compare the antitumor
efficacy of SFV and Ad vectors. We inoculated negative
control groups with 108 vp of SFV-LacZ, 108 PFU of Ad-
LacZ, or saline (Fig. 3B). We inoculated an additional
group with 15 ng of recombinant murine IL-12 (Fig. 3C).
We evaluated the efficacy of treatment by measuring the
size of tumor nodules every 3–4 days. SFV vectors
expressing IL-12 showed a strong and dose-dependent
antitumoral activity against MC38 tumors. The best
results were obtained with 108 vp of SFV-IL-12 or SFV-
enhIL-12, which induced complete tumor regressions in
80 and 92% of the animals, respectively. At lower doses
SFV-enhIL-12 was clearly more efficient than SFV-IL-12 as
shown by the fact that a dose of 107 vp of SFV-enhIL-12
induced 62% complete tumor regressions versus 36% with
SFV-IL-12. Since both vectors should have the same
infectivity in the tumor, the difference in the therapeutic
effect can be attributed only to a higher IL-12 expression
from SFV-enhIL-12. In addition, both SFV vectors were
more efficient at inducing antitumoral responses than an
adenoviral vector expressing IL-12, which at the highest
dose induced 37% total tumor regressions. Previous
studies had also shown that MC38 tumors were highly
resistant to high doses of Ad-IL-12 [31]. In control animals
(Figs. 3B and 3C) we observed only a few sporadic
regressions (2 of 21 in SFV-LacZ-treated mice, 1 of 17 in
the Ad-LacZ group, or none in the case of saline-treated
mice or mice injected with recombinant IL-12).
In Vivo Expression of IL-12 After Intratumoral
Injection of SFV Vectors Coding IL-12
The enhancement in the antitumoral response observed
with SFV-enhIL-12 compared to SFV-IL-12 suggests that
higher IL-12 expression inside the tumor could be
responsible for a better induction of a therapeutic
response. To prove that there was a higher IL-12
expression in vivo we measured IL-12 levels in both
tumors and serum after intratumoral injection of MC38
nodules with 108 vp of SFV-IL-12 or SFV-enhIL-12 or 108
PFU of Ad-IL-12. We used SFV-LacZ and Ad-LacZ at the
same doses, or saline, as negative controls. We removed
tumors at 1, 4, or 6 days after treatment and measured IL-
12 concentration in tumor homogenates by p70-specificMOLECULAR THERAPY Vol. 12, No. 1, July 2005
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inoculated with IL-12-expressing vectors at 24 h p.i.,
decreasing over time until day 6 (Fig. 4A). At day 1, SFV-
IL-12- and Ad-IL-12-treated tumors contained around 2
ng IL-12/mg total protein. In contrast, in SFV-enhIL-12-
treated tumors this level was 9.5 ng IL-12/mg total
protein. At longer times IL-12 could be detected only in
SFV-enh-IL12-treated tumors. These results showed both
a correct in vivo functioning of the SFV translational
enhancer and a correlation between higher IL-12 expres-
sion in vivo and better antitumoral effect for the SFV
vectors. In serum, IL-12 was detected only at day 1
postinjection, but at levels much lower than the intra-
tumoral concentration (Fig. 4B). Although the lower
antitumoral efficacy of the adenoviral vector could be
due to low infectivity of this vector in MC38 cells, the
fact that the level of intratumoral IL-12 concentration in
Ad-IL-12- and SFV-IL-12-treated tumors was similar sug-
gests that there could be other reasons explaining the
superiority of SFV vectors. One such reason could be
related to the induction of apoptosis by SFV in tumor
cells. This could lead to the release of tumor-specific
antigens that would be taken up by APCs at the tumor
site and presented in the context of the strong costimu-
latory signals induced by IL-12, thus eliciting an
enhanced cellular antitumoral response [34]. This
hypothesis is supported by the fact that a slight anti-
tumoral effect could also be observed when treating
tumors with a high dose of control vector SFV-LacZ. In
this case the antitumoral effect would be mediated only
by the induction of apoptosis in tumor cells. In addition,
in our study the inoculation of recombinant IL-12 into
MC38 tumors did not produce any effect, even though
the dose that was used was about twice the amount
expressed by SFV-enhIL-12.
Repeated Low Doses of SFV Vectors Expressing IL-12
Can Increase Antitumor Efficacy
In our study IL-12 expression inside the tumors could not
be detected after 6 days, probably due to the transient
nature of SFV vectors, which are cytopathic in most
mammalian cells. Although this transient nature does
not seem to be a problem when using high doses of
vector, it could compromise the therapeutic efficiency of
SFV vectors at lower doses. To study if longer IL-12
expression in MC38 tumors could increase the antitu-
moral activity of SFV vectors we evaluated the therapeu-
tic effect produced by the administration of repeated
intratumoral subtherapeutic doses of SFV vp given at
short intervals. We treated MC38 nodules intratumorally
with one or three doses of 2  106 vp of SFV-enhIL-12 or
with one or three doses of 5  106 vp of SFV-IL-12 or SFV-
enhIL-12 (Fig. 3D). We administered multiple doses every
24 or 48 h. As a negative control, we inoculated 107 vp of
SFV-LacZ using the same intervals. A single dose of SFV-
enhIL-12 produced a moderate antitumoral effect result-157
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FIG. 4. In vitro IL-12 expression after intra-
tumoral treatment with SFV vectors.
C57BL/6 mice bearing MC38 tumors were
injected intratumorally with 108 vp of the
indicated SFV vectors, 108 PFU of the
indicated Ad vectors, or saline as control.
(A) Tumors and (B) serum samples were
obtained at the indicated times and used
for IL-12 quantification. In all cases n = 6.
*P b 0.05; ns, not significant.
ARTICLEdoi:10.1016/j.ymthe.2005.02.011ing in 17 or 46% complete tumor regressions with 2  106
or 5  106 vp, respectively. In contrast, three doses of this
vector given at 48-h intervals enhanced the therapeutic
effect, increasing the number of complete tumor regres-
sions to 83 or 77%, respectively. At 24-h intervals the
antitumoral effect was also considerably improved, with
58 or 87% complete tumor regressions, respectively. A
moderate effect was observed with repeated inoculations
of 5  106 vp of SFV-IL-12, but only when these were
given every 24 h. SFV-LacZ-treated animals showed a
minimal response regardless of the number of doses or
intervals used. This study showed that administration of
repeated low doses of SFV-enhIL-12 can increase consid-
erably the antitumoral effect of this vector. The use of low
doses of viral vectors may offer several advantages, like a
higher biosafety and, in the case of vectors expressing IL-
12, the reduction of toxic effects associated with this
cytokine. However, repetitive use of vectors could induce
immune responses against the vector itself, inhibiting its
therapeutic efficacy.
Systemic Immunization with SFV vp Does Not Prevent
the Induction of an Antitumoral Response with SFV
Vectors Expressing IL-12
SFV vectors have been reported as poorly immunogenic,
being able to induce a weak immune response against
vector viral proteins [35]. Although this is probably the
case when using low doses of virus, the injection of high
doses of SFV vp can generate a neutralizing immuneFIG. 3. Antitumoral effect in mice bearing MC38 tumors treated with SFV
intratumorally with the indicated dose of SFV-enhIL-12 or SFV-IL-12 or with the sa
with 108 vp of SFV-LacZ, 108 PFU of Ad-LacZ, or saline. (C) An additional control
Each line represents the evolution of tumor size over time for each individual m
animals after treatment in each group is indicated in each graph. (D) Groups of C
times at the indicated intervals and doses with SFV vectors. Results are shown a
Tumor-free animals were defined as those mice that completely rejected tum
developing new nodules.
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same vector in subsequent administrations (unpublished
results). Since treatment of large tumors could require the
use of several administrations of the vector it was of great
interest to study if previous inoculations with SFV vp had
any effect on the capacity of SFV to infect tumors or on its
antitumoral efficacy. In our MC38 tumor model, we
inoculated mice intravenously (iv) or intraperitoneally
(ip) with 106 or 108 vp of SFV-Luc at days 1 and 20. Two
weeks after the second immunization subcutaneous
MC38 tumors were induced and when they reached a 5-
mm diameter we injected them with 108 vp of SFV-Luc to
check infectivity or with the same dose of SFV-enhIL-12
to check the antitumoral effect (in this case only those
mice receiving 108 vp of SFV-Luc were treated). We took
samples of serum before treatment from all animals and
tested for the presence of anti-SFV neutralizing antibodies
as described under Materials and Methods. Animals
receiving two doses of 106 SFV vp showed low titers of
neutralizing antibodies (100 and 900 when immunized ip
or iv, respectively). However, animals immunized with
108 SFV vp developed very high titers of neutralizing
antibodies (N20,000). Nevertheless, the induction of a
neutralizing immune response against SFV was not able
to prevent local expression of luciferase in tumor nodules
injected with SFV-Luc (Fig. 5), and only a moderate
reduction in luciferase expression was observed in mice
that had been preimmunized iv. These results indicate
that SFV vectors are able to express genes locally invectors expressing IL-12. (A) Groups of tumor-bearing mice were injected
me PFU doses of Ad-IL-12. (B) Control animals were inoculated intratumorally
group was inoculated intratumorally with 15 ng of recombinant murine IL-12.
ouse. The number of treated animals as well as the percentage of tumor-free
57BL/6 mice bearing MC38 tumors were injected intratumorally one or three
s the percentage of tumor-free animals after treatment. In all groups n = 12.
ors and survived during the time of the study (at least 6 months) without
159
FIG. 5. Effects of preimmunization of mice with SFV vp in intratumora
infectivity. Mice were inoculated systemically (ip or iv) with 106 or 108 vp of SFV
Luc at days 1 and 20. Two weeks later, MC38 tumors were induced and treated
with 108 vp of SFV-Luc. Luciferase expression was analyzed at 48 h post
inoculation. A group of nonimmunized mice and a group of mice immunized
but not injected intratumorally with SFV-Luc (nontreated) were used as positive
and negative controls, respectively. In all groups n = 3. *P V 0.05; ns, no
significant.
FIG. 6. Specific CTL activity after intratumoral injection of SFV vectors expre
treated with the indicated SFV vectors or with saline. Specific lysis activity w
mytomicin-C-treated spleen cells from naRve animals incubated with KSP pep
incubated (n) with KSP peptide, as target cells. Continuous lines, mice that
Numbers in the upper right corner of each graph indicate number of mice t
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ttumors even when high titers of anti-SFV systemic
neutralizing antibodies are present. To test the antitu-
moral efficacy of IL-12-expressing SFV vectors in pre-
immunized mice, we treated groups of ip or iv
immunized animals that had received two doses of
108 vp of SFV-Luc intratumorally with 108 vp of SFV-
enhIL-12 as described. Tumor size decreased in all
treated mice independent of the preimmunization
route, resulting in 60% total tumor regressions (n =
10). Although this therapeutic effect was lower than
that observed in a nonpreimmunized control group, in
which 80% of tumors regressed completely, it indicates
that SFV vectors expressing IL-12 can be used locally forssin
as m
tide
had
hatantitumoral treatment even if high titers of neutralizing
antibodies against the vector are present.
Characterization of the Cellular Immune Response
Involved in the Antitumoral Effect Mediated by
IL-12-Expressing SFV Vectors
Antitumoral responses induced by IL-12-expressing vec-
tors have been reported to be mediated by the induction
of a strong cellular immune response against the tumor.
We have investigated which T cell types were involved in
the antitumoral response observed in animals treated
with SFV vectors. To this end we carried out depletions of
CD4+ and/or CD8+ T cells or of NK cells in MC38 tumor-
bearing mice previous to treatment with 108 vp of SFV-IL-
12 or SFV-enh-IL-12. CD8+ T cell depletion abrogated
completely the antitumoral effect of SFV vectors express-
ing IL-12 (data not shown). However, tumor remission
was not affected by CD4+ T cell or NK depletion since
these animals were able to eliminate tumor nodules
similar to nondepleted animals. These results showed a
critical role for CD8+ T cells in the antitumoral effect
mediated by SFV vectors expressing IL-12. To determine if
CTLs against MC38 cells had been generated we treated
tumor-bearing mice intratumorally with 108 vp of SFV-IL-
12, SFV-enhIL-12, SFV-LacZ, or saline and 15 days later
carried out a specific CTL assay to analyze cytotoxic
activity against MC38 tumor-associated antigen KSP [36]
(Fig. 6). We observed a high specific lysis only in SFV-IL-
12- or SFV-enhIL-12-treated animals that had rejected
tumors (Fig. 6). This is in contrast to observations made
by Asselin-Paturel et al. [24], who saw no CTL response
induced by a similar SFV vector expressing IL-12 in a
melanoma mouse model.
Induction of Long-Term Antitumoral Immunity in
Mice Treated with SFV Vectors Expressing IL-12
To evaluate if treatment with SFV vectors expressing IL-12
had generated a long-lasting immunological memoryg IL-12. Splenocytes were extracted from tumor-bearing mice that had been
easured in a standard 5-h 51Cr release assay after in vitro restimulation with
as described. Lysis was assayed using the EL-4 cell line, incubated (.) or no
completely rejected tumors; dashed lines, mice that had not rejected tumors
rejected tumors/total number of mice.
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ARTICLEdoi:10.1016/j.ymthe.2005.02.011against tumor cells in animals that had rejected MC38
tumors, we rechallenged these mice with the same tumor
cells 3 months after complete remission of the primary
tumor. Cured animals received a subcutaneous injection
of 5  105 MC38 cells in the left flank and a second
injection of 5 105 cells of the unrelated tumor LLC or EL-
4 in the right flank. A control group of naRve animals
received both subcutaneous injections. All control mice
developed tumor nodules in both flanks (n = 5). In
contrast, all animals that had eliminated the initial
MC38 tumor were fully protected against MC38 rechal-
lenge (n = 20), while 80 or 100% of them developed the
unrelated LLC or EL-4 tumor nodules, respectively. These
data indicate that a specific long-term antitumoral
immunity had been induced after intratumoral injection
of SFV-derived vectors.
We have shown that SFV vectors expressing IL-12 can
be a good alternative for the treatment of tumors that
have been hard to treat with other viral vectors such as
adenovirus. The amount of IL-12 expressed in the tumor
seems to be crucial for the efficacy of the treatment, and
SFV vectors are able to provide very high expression
levels, especially by using the capsid translation
enhancer. These vectors combine a good antitumoral
efficacy with a high degree of biosafety, in part due to
their transient nature, being able to function efficiently
even in animals having high titers of neutralizing anti-
bodies against the vector.
MATERIALS AND METHODS
Construction of SFV IL-12 vectors. Plasmids pSFV1, pSFV3-LacZ, and
pSFVb1-2A have been previously described and were kindly provided by
Dr. P. Liljestrfm (Karolinska Institute, Stockholm) [9,37,38]. Plasmid pBS-
IL-12 has also been described and was kindly provided by Dr. C. Qian [39].
To construct pSFV-IL-12, a XhoI/SpeI fragment from pBS-IL-12 containing
a p35-IRES-p40 cassette was inserted into the BamHI site in pSFV1, all sites
being previously blunted with Klenow. pSFV-enhIL-12 was generated in
two steps. First, mouse IL-12 p35 and p40 genes were amplified from pBS-
IL-12 by PCR with primers TACTCCCCGGGAATCACGCTACCTCCTC
and TCCACCCGGGTCGCGACTATCAGGCGGAGCTCAGATAG for p35
and AGGATCCCGGGCCTCAGAAGCTAACCATCTC and GGATCCC-
GGGTCGCGATCACTAGGATCGGACCCTGCAGG for p40. XmaI (in
bold) and NruI (underlined) sites were included to facilitate cloning into
pSFVb1-2A. The 648- and 1020-bp PCR fragments corresponding to p35
and p40 genes, respectively, were digested with XmaI and inserted into
the XmaI site in pSFVb1-2A, generating pSFVb1-2A-p35 and pSFVb1-2A-
p40, respectively. In a second step a BglII/StuI fragment containing p40
was digested from pSFVb1-2A-p40 and inserted into the NruI site in
pSFVb1-2A-p35, all sites being previously blunted with Klenow, yielding
pSFV-enhIL-12. pSFV-Luc was generated by inserting the 1.7-kb HindIII/
XbaI fragment from the SV40Luc plasmid (Promega, Madison, WI, USA)
into the BamHI in pSFV1, all sites being previously treated with Klenow.
Animals and cell lines. Female 4- to 6-week-old C57BL/6 mice were
purchased from Harlan (Spain). BHK-21 cells were cultured as described
[9]. The MC38 adenocarcinoma cell line [32] and LLC [40] cell line were
grown in DMEM (Gibco BRL, UK) supplemented with 10% FCS, 2 mM
glutamine, and antibiotics. The L3T4 CD4+-specific rat anti-mouse
hybridoma GK1.5, the CD8+-specific rat anti-mouse hybridoma
H35.17.2, and the EL-4 cell line were grown in RPMI 1640 (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% FCS myoclone, 2 mMMOLECULAR THERAPY Vol. 12, No. 1, July 2005
Copyright C The American Society of Gene Therapyglutamine, and antibiotics. MC38 and LLC cell lines and hybridomas
were kindly provided by Dr. I. Melero.
Transfection of cells and virus production. RNA synthesis and trans-
fection into BHK-21 cells by electroporation was performed as described
previously [41]. Packaging of recombinant RNA into SFV vp was
performed by coelectroporation of BHK-21 cells with the recombinant
RNA and both helper-S2 and helper-C-S219A SFV RNAs as described [11].
SFV particles were purified by ultracentrifugation as described previously
[42]. Indirect immunofluorescence of infected BHK-21 cells was per-
formed to determine the titer of recombinant virus stocks [43]. A Mab
specific for SFV replicase was used as primary antibody (kindly provided
by W. Bodemer). Titers of approximately 5  109 vp/ml were usually
obtained after purification, the average production yield being about 250
vp/cell. Recombinant adenovirus Ad-IL-12 and Ad-LacZ carrying either
the IL-12 p35-IRES-p40 cassette or the LacZ gene under the transcriptional
control of the CMV promoter, respectively, have already been described
[39] and were kindly provided by Dr. C. Qian. The particle-to-infectious
particle (PFU) ratio for Ad-IL-12 and Ad-LacZ vectors was of 35 and 10,
respectively.
Analysis of gene expression. Metabolic labeling of SFV-transfected cells
was performed as previously described [41], but using a mixture of [35S]
methionine and [35S] cysteine as labeling medium. Supernatants were
precipitated with 20% TCA before being loaded onto the gel. Western blot
analysis of the same samples under nonreducing conditions was
performed using as primary antibodies anti-IL-12-p40 for supernatants
(Pharmingen, USA) or anti-actin for lysates (Sigma, USA), respectively.
Production of IL-12 in supernatants of cells infected with SFV or
adenovirus vectors was determined by using a specific p70 ELISA kit
(Pharmingen). To measure in vivo production of IL-12 or luciferase,
tumors from treated animals were frozen, homogenized in 300 Al of PBS
with protease inhibitors (protease inhibitor cocktail tablets; Roche,
Switzerland), and centrifuged for 5 min at 9300g. Supernatants were used
for cytokine determination by p70 ELISA or for luciferase detection using
a conventional luminometer.
Induction, infection, and treatment of MC38 tumors. C57BL/6 female
mice were subcutaneously injected with 5  105 MC38 cells resuspended
in 100 Al of HBSS. When tumors reached 5 mm in diameter, SFV vp,
adenovirus vector, or recombinant IL-12 (PeproTech, USA) resuspended in
a total volume of 60 Al of saline buffer was injected intratumorally. When
SFV-LacZ was used for infectivity studies, tumors were excised, embedded
in OCT (Tissue Tek, Zoeterwoude, The Netherlands), and frozen in liquid
N2. Sections of 6 Am were fixed with 0.5% glutaraldehyde and stained
with X-gal. For analysis of infectivity with SFV-Luc, mice were anesthe-
tized and injected intraperitoneally with 100 Al of d-luciferin at 30.3 Ag/
ml (Xenogen Corp., USA). Luciferase activity images were acquired with
an IVIS charge-coupled-device camera system (Xenogen Corp.) and
analyzed with the LivingImage 2.20 software package (Xenogen Corp.).
For treatment studies tumor growth was monitored every 3–4 days by
measuring two perpendicular tumor diameters and considering the
average diameter as an indicator of tumor size.
Evaluation of anti-SFV neutralizing antibodies in preimmunized mice.
The presence of SFV neutralizing antibodies in serum of preimmunized
animals was analyzed by performing an in vitro infection assay in the
presence of different amounts of sera from the immunized animals.
Briefly, sera from each group of animals were pooled, diluted by doing
10-fold serial dilutions with infection medium (MEM containing 0.2%
BSA, 2 mM glutamine, and 20 mM Hepes), mixed with 5  105 vp of
SFV-Luc in a total volume of 200 Al, and incubated for 1 h at 378C. This
mixture was used to infect monolayers of BHK cells in 96-well plates
(104 cells/well) (the approximate m.o.i. that was used was 50). At 24 h
p.i. the inoculum was removed and 50 Al of d-luciferin (0.15 Ag/ml) was
added per well for luciferase activity measurement. Luciferase activity
images of the plates were acquired with the IVIS charge-coupled-device
camera system (Xenogen Corp.) and analyzed with the LivingImage
2.20 software package (Xenogen Corp.). The neutralizing titer was
defined as the inverse of the maximum serum dilution able to reduce161
ARTICLE doi:10.1016/j.ymthe.2005.02.011luciferase activity to 50% of the activity observed in cells infected with
SFV-Luc previously incubated with control serum from nonimmunized
animals.
Depletion of lymphocytes and CTL assays. Depletions of CD4+, CD8+, or
NK cells were performed by intraperitoneal injection of specific antibodies
as previously described [39], but injecting antibodies at days 1 and +7.
Depletions were monitored by FACS analysis of PBMC stained with
fluorochrome-tagged anti-CD4+, anti-CD8+, or anti-NK1.1, respectively,
and only mice with a depletion efficacy higher than 99% for each specific
cell type were used in the study. Groups of six mice were used for each
depletion study with each of the vectors, except in double-depleted
animals (CD4+ and CD8+), for which only three animals were used per
group. CTL assay was performed in a conventional 5-h 51Cr assay as
described [44], incubating splenocytes from treated mice with the H-2Kb-
restricted peptide derived from the MuLV envelope–p15E region
KSPWFTTL (KSP) [36] and using EL-4 cells loaded with 51Cr and with or
without KSP peptide as target cells.
Statistical analysis. All error terms are expressed as the standard
deviation of the mean (SD). Significance levels for comparison of
differences between groups were analyzed using the Mann–Whitney U
test, except in Figs. 4A and 4B, for which ANOVA or the Student t test was
used, respectively, and in Fig. 5, for which the Kruskal–Wallis test
followed by Mann–Whitney U test was used.
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